Company intelligence / Profile preview

Nephrolyx

Berlin-Adlershof, Berlin, Germanynephrolyx.com ↗

Ownership: Private
Development stage: Other

Overview

Nephrolyx has developed a rapid, highly precise diagnostic kit and digital platform for measuring glomerular filtration rate (mGFR) using iohexol clearance. Their solution provides same-day results (<6 hours), is more accurate than conventional biomarker-based estimates, and is used across European clinics to improve early detection of acute and chronic kidney diseases. The technology is based on over a decade of research at Charité Universitätsmedizin Berlin.

Therapeutic areas: Nephrology
Modalities: DeviceSoftware platformDiagnostic kit (IVD)
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Nephrolyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nephrolyx.

Explore the full profile